Sepsis is a life-threatening condition caused by the body’s response to a bacterial, fungal or viral infection. Most frequently, it affects adults over the age of 65, children younger than one year of age, people with chronic medical conditions such as diabetes, lung disease, cancer, and kidney disease, as well as those with a weakened immune system.

Unfortunately, sepsis is still a common occurrence with an estimated 50 million cases occurring worldwide each year.

It is one of the most common causes of death for hospitalised patients in European countries with a high mortality rate of 30-40%.

Even though the prescription of antibiotics and the establishment of Intensive Care Units (ICUs) have already greatly reduced the number of sepsis-related deaths, the introduction of an immunotherapy approach is intended to greatly improve the outcome of the disease for those affected.

While antibiotics and Intensive Care Units (ICUs) have significantly improved survival rates, a more targeted approach is needed to further enhance treatment outcomes.

ImmunoSep addressed this need by pioneering a personalised immunotherapy approach. Unlike conventional ‘one-size-fits-all’ treatments, ImmunoSep recognised that immune responses in sepsis—ranging from overinflammation to immunoparalysis—vary among patients.

By adopting a precision medicine strategy, ImmunoSep aimed to revolutionise sepsis treatment, improving patient outcomes and paving the way for future advancements in immune-based therapies.